Andrea N Traina1, Melinda E Lull2, Adrian C Hui3, Toni M Zahorian4, Jane Lyons-Patterson5. 1. AstraZeneca LP, Fort Washington, Pennsylvania, USA. 2. AstraZeneca LP, Fort Washington, Pennsylvania, USA; St. John Fisher College, Wegmans School of Pharmacy, Rochester, USA. Electronic address: mlull@sjfc.edu. 3. MedStar Union Memorial Hospital, Baltimore, USA. 4. Boston Medical Center, Boston, USA. 5. Rochester General Health System, Rochester, USA.
Abstract
OBJECTIVE: The use of once-weekly exenatide in type 2 diabetes mellitus is well supported, but little is known about its effectiveness in type 1 diabetes. The objective of this study was to determine the clinical efficacy of once-weekly exenatide on glycemic control in patients with type 1 diabetes when added to basal-bolus insulin therapy. METHODS: For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included. Demographic information, glycated hemoglobin (A1C), body weight, body mass index, systolic and diastolic blood pressures, total daily insulin dose, basal and bolus insulin doses, 28-day continuous subcutaneous insulin infusion glucose average and incidence of hypoglycemia were collected at baseline and 3 months after beginning therapy with once-weekly exenatide. RESULTS: An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria. Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015). CONCLUSIONS: This study revealed that the addition of once-weekly exenatide to insulin therapy for type 1 diabetes patients leads to significant improvements in A1C, body weight, body mass index and insulin doses.
OBJECTIVE: The use of once-weekly exenatide in type 2 diabetes mellitus is well supported, but little is known about its effectiveness in type 1 diabetes. The objective of this study was to determine the clinical efficacy of once-weekly exenatide on glycemic control in patients with type 1 diabetes when added to basal-bolus insulin therapy. METHODS: For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included. Demographic information, glycated hemoglobin (A1C), body weight, body mass index, systolic and diastolic blood pressures, total daily insulin dose, basal and bolus insulin doses, 28-day continuous subcutaneous insulin infusion glucose average and incidence of hypoglycemia were collected at baseline and 3 months after beginning therapy with once-weekly exenatide. RESULTS: An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria. Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015). CONCLUSIONS: This study revealed that the addition of once-weekly exenatide to insulin therapy for type 1 diabetespatients leads to significant improvements in A1C, body weight, body mass index and insulin doses.
Authors: Kamal K Mahawar; Nimantha De Alwis; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: Allison L Brill; Jaclyn A Wisinski; Mark T Cadena; Mary F Thompson; Rachel J Fenske; Harpreet K Brar; Michael D Schaid; Renee L Pasker; Michelle E Kimple Journal: Mol Endocrinol Date: 2016-04-06